Bio technologies are used to understand how factors of your genetics predispose you to autoimmune diseases and cancer. MicroRNAs have a direct impact on the genes in the whole genome and regulate diverse aspects of development and physiology. Human diseases such as cancer and autoimmune diseases develop when miRNA function is impaired.
Doctors can screen all of an organism’s genes to identify a disease and develop an appropriate treatment. This has been the pursuit of Dr. Clay Siegall. In 1998 he obtained his Ph.D. in Genetics from George Washington University. He is co-founder of Seattle Genetics, Inc. where he currently serves as President, Chief Executive Officer and Chairman of the Board.
Seattle Genetics advances innovative antibody-drug conjugates (ADC) in the study and treatment of cancer. These potent cancer killing cytotoxic drugs (toxic to cells) allow improved targeted therapy. They can discriminate between healthy tissue and destroy only the diseased tissue. Brentuximab vedotin (Adcetris) is one of these anti-cancer chemotherapy drugs used in clinical trials around the world. It’s exciting that in compliance with the U.S. Food and Drug Administration standards Seattle Genetics has requested a Biologics License Application from the FDA to introduce Adcetris internationally.
Dr. Siegall brings Seattle Genetics to the forefront as a leader in antibody-drug conjugate clinical and pre-clinical applications. His background in pharmaceutical, cancer, bio-technology and bio-pharmacology has aided his success with their (ADC) platform. Since 2001 he has secured more than $330 million through private and public funding, including Seattle Genetics initial offering. He’s also generated $65 million through collaboration agreements with Genentech, Curagen, Medimmune, Bayer and Progenics. Seattle Genetics has made substantial investments in their pipeline products. Thrilling advances and promising early data is on-going.
ADCs play an integral role in treating cancer and autoimmune diseases. Anti-body drug conjugates are founded on past pharmaceutical and genetic studies and developments and now Seattle Genetics optimizes them for the future.
Read more about Siegall: